Clinical Takeaway
Clinical trials show that cannabis-based products, particularly those containing THC, provide modest reductions in chronic pain compared to placebo, though the overall quality of evidence remains low to moderate. Benefits appear most consistent for neuropathic and mixed pain conditions, while the risk of adverse effects, including dizziness and cognitive changes, must be weighed against potential gains. Patients and clinicians should make individualized decisions based on pain type, product composition, and tolerance for side effects.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This systematic review provides clinicians with updated evidence on the efficacy and safety profile of cannabinoid-based therapies for chronic pain management, addressing persistent clinical uncertainty about their role in current treatment algorithms. The dual review methodology and strength-of-evidence assessment enable evidence-based risk-benefit discussions with patients considering cannabinoids as adjunctive or alternative analgesic options. The THC-to-CBD ratio categorization offers mechanistic clarity that may guide product selection and inform personalized dosing strategies for heterogeneous chronic pain populations.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
💊 This updated systematic review adds important nuance to the cannabis-for-pain conversation by examining randomized controlled trials through the lens of THC:CBD ratios, a distinction often lost in clinical practice and patient discussions. While the review acknowledges that evidence for cannabinoid efficacy and safety in chronic pain remains uncertain, the stratification by cannabinoid composition suggests that not all cannabis products function equivalently—a critical point given the heterogeneity of products available to patients and the wide variation in how they’re formulated and marketed. Key limitations include the relatively small number of high-quality trials, the challenge of adequate blinding in cannabis studies, publication bias favoring positive results, and the fact that most research focuses on specific pharmaceutical formulations rather than whole-plant products patients typically access. Clinically, this reinforces the principle that when considering cannabis for chronic pain, we should move beyond simple yes-or-no recommendations and instead engage patients in informed discussions about specific product composition, the modest evidence base, realistic expectations about effect size, and potential drug